MXCT

MaxCyte Inc

MXCT.US maxcyte.com + Research + Basket
CIK 0001287098
Employees 91
Phone 301 944 1700
Fiscal year end December
IPO Jul 30, 2021
Address 9713 Key West Avenue, Rockville, MD, United States, 20850
1.39
-0.07 (-4.79%)
USD · NASDAQ
52-week range
0.64
1.81
Trading at 64% of the 52-week range
Market Cap
150.68M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.50
Div. Yield
N/A
% Institutions
65.25%
% Insiders
1.84%

1 Year

-13.7%

3 Year

-60.3%

10 Year

-91.8%
Description

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Actions

Add an action for MXCT.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Maher Masoud President, CEO & Executive Director 1976
Mr. Parmeet Ahuja Chief Financial Officer 1969
Mr. Jay Gelfman Chief Operations Officer NA
Ms. Ana-Paula Martins Fernandes Senior Vice President of Global Sales NA
Mr. Sidharth Kapileshwar Chief Corporate Development Officer NA
Ms. Jill Mayer Senior Vice President of Human Resources NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 17, 2026 Douglas J Swirsky N/A Sale 10.14K $0.81 $8.22K SEC
Aug 13, 2025 Douglas J Swirsky N/A Purchase 50.00K $1.29 $64.50K SEC
Aug 13, 2025 Maher Masoud N/A Purchase 75.00K $1.37 $102.75K SEC
Aug 13, 2025 Richard Douglas N/A Purchase 80.00K $1.39 $111.20K SEC
Aug 13, 2025 Stanley C Erck N/A Purchase 100.00K $1.37 $137.00K SEC
Aug 13, 2025 William W Brooke N/A Purchase 50.00K $1.29 $64.50K SEC
Jun 25, 2025 Rekha Hemrajani N/A Sale 10.68K $2.09 $22.33K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Capricorn Fund Managers Ltd 8.20M Jun 30, 2026 7.95% $0.80 0.00%
Vitruvian Partners 5.04M Jun 30, 2026 4.89% $3.09 0.00%
Vanguard Capital Management, LLC 4.03M Jun 30, 2026 3.91% $0.00 1.24%
Morgan Stanley - Brokerage Accounts 3.69M Jun 30, 2026 3.58% $0.00 0.16%
Mudita Advisors LLP 3.37M Jun 30, 2026 3.27% $0.86 0.00%
BlackRock Inc 3.06M Jun 30, 2026 2.97% $0.00 -65.21%
Brooklands Fund Management Limited 2.85M Jun 30, 2026 2.76% $2.87 30.05%
BNP Paribas Investment Partners SA 2.77M Jun 30, 2026 2.69% $0.00 0.00%
Cadian Capital Management LP 2.20M Jun 30, 2026 2.13% $0.20 27.76%
Peapod Lane Capital LLC 2.13M Jun 30, 2026 2.06% $1.76 59.57%
Renaissance Technologies Corp 1.91M Jun 30, 2026 1.85% $0.00 -4.13%
AQR Capital Management LLC 1.88M Jun 30, 2026 1.82% $0.00 54.18%
Jane Street Group LLC 1.56M Jun 30, 2026 1.51% $0.00 7,498.83%
Two Sigma Investments LLC 1.46M Jun 30, 2026 1.42% $0.00 140.55%
Geode Capital Management, LLC 1.33M Jun 30, 2026 1.29% $0.00 -43.84%
RBF LLC 1.32M Jun 30, 2026 1.28% $0.07 0.00%
The Goldman Sachs Group Inc 1.24M Jun 30, 2026 1.20% $0.00 7.15%
Millennium Management LLC 1.20M Jun 30, 2026 1.17% $0.00 2,698.30%
NANO CAP NEW MILLENNIUM GROWTH FUND L P 1.20M Jun 30, 2026 1.16% $1.14 20.00%
Marshall Wace Asset Management Ltd 1.01M Jun 30, 2026 0.98% $0.00 925.94%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 AXA Framlington Health Fund - R Income 2.77M 2.69% ▲ 0.00% Jul 31, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 2.74M 2.66% ▲ 0.00% Sep 30, 2026
3 Liontrust UK Listed Smaller Coms B Acc 2.73M 2.64% ▼ 28.29% Jul 31, 2026
4 Unicorn AIM VCT Ord 2.49M 2.41% ▲ 0.00% Sep 30, 2026
5 Liontrust Instl UK Lstd Smlr Coms P Acc 1.75M 1.70% ▲ 0.00% Jul 31, 2026
6 River UK Micro Cap Ord 834.10K 0.81% ▲ 0.00% Jun 30, 2026
7 MI Chelverton UK Equity Growth B Acc 700.00K 0.68% ▲ 0.00% Sep 30, 2026
8 Fidelity Extended Market Index 551.80K 0.53% ▼ 0.53% Aug 31, 2026
9 Morgan Stanley Inst Inception I 347.43K 0.34% ▲ 0.00% Jun 30, 2026
10 EQ/Morgan Stanley Small Cap Growth K 288.25K 0.28% ▲ 0.00% Aug 31, 2026

Financial Highlights

▼
Market Cap: $150.68M
EBITDA: $-30.29M
Book Value: $1.50
Earnings/Share: $-0.34
Profit Margin: -114.77%
Operating Margin: -140.72%
ROA (TTM): -10.64%
ROE (TTM): -20.39%
Revenue (TTM): $31.05M
Revenue/Share (TTM): $0.29
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -14.50%

Valuation Metrics

Enterprise Value: $60.18M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 103.21M
Shares Float: 93.72M
% Insiders: 1.84%
% Institutions: 65.25%
Shares Short: 1.83M
Shares Short (Prior Month): 1.09M
Short Ratio: 1.81
Short % Float: 1.79%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$33.03M
Cost of Goods Sold
adjust
$-6.22M
Gross Profit
subtotal
$26.80M
SG&A
adjust
$-28.12M
R&D
adjust
$-20.82M
Other Operating Expense
adjust
$-23.15M
Operating Income
subtotal
$-45.29M
Other / Non-Operating Items
adjust
$655.00K
Net Income
subtotal
$-44.63M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about MXCT.US!